Marie-joelle J. Mozziconacci

Marseille, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications

Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.

Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.

Journal: Leukemia
Published: August 25, 2025

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study.

Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study.

Journal: Blood cancer journal
Published: May 04, 2025

Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.

Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.

Journal: Annals of hematology
Published: May 02, 2024

Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.

Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.

Journal: European journal of haematology
Published: April 03, 2024

Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.

Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.

Journal: Leukemia
Published: April 03, 2024

Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.

Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.

Journal: Leukemia & lymphoma
Published: February 08, 2024

The t(X;20)(q13;q13) translocation is a good prognostic factor in myeloid neoplasms: A report of 25 cases from the Groupe Francophone de Cytogénétique Hématologique.

The t(X;20)(q13;q13) translocation is a good prognostic factor in myeloid neoplasms: A report of 25 cases from the Groupe Francophone de Cytogénétique Hématologique.

Journal: American journal of hematology
Published: December 20, 2023

Molecular landscape of mature B-cell lymphoproliferative disorders with BCL3-translocation: A Groupe Francophone de Cytogénétique Hématologique (GFCH)/French Innovative Leukemia Organization (FILO) study.

Molecular landscape of mature B-cell lymphoproliferative disorders with BCL3-translocation: A Groupe Francophone de Cytogénétique Hématologique (GFCH)/French Innovative Leukemia Organization (FILO) study.

Journal: American journal of hematology
Published: November 28, 2023

Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.

Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.

Journal: European journal of haematology
Published: August 03, 2023

Erythroleukemia: Classification.

Erythroleukemia: Classification.

Journal: EJHaem
Published: February 03, 2023

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.

Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.

Journal: Cancers
Published: March 08, 2022

Multiple cytogenetics forms of KMT2A amplification and jumping translocation in a case of myelodysplastic syndrome.

Multiple cytogenetics forms of KMT2A amplification and jumping translocation in a case of myelodysplastic syndrome.

Journal: EJHaem
Published: September 20, 2021
Showing 1-12 of 46

Last Updated: 09/26/2026